摘要: Myriad bi-specific proteins have been developed that recognize two different clinical targets, with the goal of achieving enhanced therapeutic effects as compared interact only one target. These engineered are starting to enter testing for a variety biomedical applications, particularly cancer treatment.
sciencemag.org参考文章(30)
Patrick Chames, Daniel Baty, Bispecific antibodies for cancer therapy mAbs. ,vol. 1, pp. 276- 283 ,(2009) , 10.4161/MABS.1.6.10015
R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler, H. Einsele, C. Brandl, A. Wolf, P. Kirchinger, P. Klappers, M. Schmidt, G. Riethmuller, C. Reinhardt, P. A. Baeuerle, P. Kufer, Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody Science. ,vol. 321, pp. 974- 977 ,(2008) , 10.1126/SCIENCE.1158545
T. Ben-Kasus, B. Schechter, S. Lavi, Y. Yarden, M. Sela, Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis Proceedings of the National Academy of Sciences of the United States of America. ,vol. 106, pp. 3294- 3299 ,(2009) , 10.1073/PNAS.0812059106
J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, Rafael G. Amado, A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 672- 680 ,(2009) , 10.1200/JCO.2008.19.8135
Lawrence G. Lum, Pamela A. Davol, Randall J. Lee, The new face of bispecific antibodies: targeting cancer and much more. Experimental Hematology. ,vol. 34, pp. 1- 6 ,(2006) , 10.1016/J.EXPHEM.2005.07.013
Matthew G. Fury, Allan Lipton, Katherine M. Smith, Corinne B. Winston, David G. Pfister, A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunology, Immunotherapy. ,vol. 57, pp. 155- 163 ,(2007) , 10.1007/S00262-007-0357-5
Joshua Silverman, Qiang Lu, Alice Bakker, Wayne To, Amy Duguay, Ben M Alba, Richard Smith, Alberto Rivas, Peng Li, Hon Le, Erik Whitehorn, Kevin W Moore, Candace Swimmer, Victor Perlroth, Martin Vogt, Joost Kolkman, Willem Pim C Stemmer, Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains Nature Biotechnology. ,vol. 23, pp. 1556- 1561 ,(2005) , 10.1038/NBT1166
Michael Dechant, Wencke Weisner, Sven Berger, Matthias Peipp, Thomas Beyer, Tanja Schneider-Merck, Jeroen J. Lammerts van Bueren, Wim K. Bleeker, Paul W.H.I. Parren, Jan G.J. van de Winkel, Thomas Valerius, Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Research. ,vol. 68, pp. 4998- 5003 ,(2008) , 10.1158/0008-5472.CAN-07-6226
Nazzareno Dimasi, Changshou Gao, Ryan Fleming, Robert M. Woods, Xiao-Tao Yao, Lena Shirinian, Peter A. Kiener, Herren Wu, The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators Journal of Molecular Biology. ,vol. 393, pp. 672- 692 ,(2009) , 10.1016/J.JMB.2009.08.032
Jitra Kriangkum, Biwen Xu, Les P. Nagata, R.Elaine Fulton, Mavanur R. Suresh, Bispecific and bifunctional single chain recombinant antibodies. Biomolecular Engineering. ,vol. 18, pp. 31- 40 ,(2001) , 10.1016/S1389-0344(01)00083-1